<DOC>
	<DOCNO>NCT01089517</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy E10030 intravitreous injection administer combination Lucentis® control Lucentis® alone subject subfoveal choroidal neovascularization secondary age-related macular degeneration ( AMD ) .</brief_summary>
	<brief_title>A Safety Efficacy Study E10030 ( Anti-PDGF Pegylated Aptamer ) Plus Lucentis Neovascular Age-Related Macular Degeneration</brief_title>
	<detailed_description>Subjects randomize 1:1:1 ratio follow dose group : - E10030 0.3 mg/eye + Lucentis® 0 . 5 mg/eye - E10030 1.5 mg/eye + Lucentis® 0 . 5 mg/eye - E10030 sham + Lucentis® 0 . 5 mg/eye Subjects treat active E10030 sham E10030 combination Lucentis® Day 0 , Week 4 , Week 8 , Week 12 , Week 16 Week 20 . Primary Efficacy Endpoint : The primary efficacy endpoint mean change visual acuity baseline Week 24 visit Safety Endpoints : Safety endpoint include adverse event , vital sign , ophthalmic variable [ visual acuity , intraocular pressure ( IOP ) , ophthalmic examination , color fundus photography , fluorescein angiogram ( FA ) , optical coherence tomography ( OCT ) ] , laboratory variable . Approximately 444 subject randomize one three treatment cohort ( approximately 148 patient per dose group ) .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Subfoveal choroidal neovascularization ( CNV ) due AMD Any follow underlying disease include : Diabetes mellitus History evidence severe cardiac disease ( e.g. , NYHA Functional Class III IV see Appendix 19.6 ) , history clinical evidence unstable angina , acute coronary syndrome , myocardial infarction coronary artery revascularization within 6 month , ventricular tachyarrhythmias require ongoing treatment . Clinically significant impair renal hepatic function . Stroke ( within 12 month trial entry ) . Any major surgical procedure within one month trial entry . Known serious allergy fluorescein dye use angiography ( mild allergy amenable treatment allowable ) , component ranibizumab ( Lucentis ) formulation , component E10030 formulation</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>